Recruitment Practices in Multicenter Randomized Clinical Trials: Time for a Relook.
作者信息
Gaba Prakriti, Bhatt Deepak L
机构信息
Division of Cardiovascular Medicine Brigham and Women's HospitalHarvard Medical School Boston MA.
出版信息
J Am Heart Assoc. 2021 Nov 16;10(22):e023673. doi: 10.1161/JAHA.121.023673. Epub 2021 Nov 15.
Abstract
摘要
相似文献
1
Recruitment Practices in Multicenter Randomized Clinical Trials: Time for a Relook.多中心随机临床试验中的招募实践：是时候重新审视了。
J Am Heart Assoc. 2021 Nov 16;10(22):e023673. doi: 10.1161/JAHA.121.023673. Epub 2021 Nov 15.
2
Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.经皮冠状动脉介入治疗患者中普拉格雷与替格瑞洛的头对头比较：一项随机对照试验的荟萃分析。
J Interv Cardiol. 2017 Oct;30(5):457-464. doi: 10.1111/joic.12416. Epub 2017 Aug 13.
3
Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial.年龄和体重调整剂量的普拉格雷与替格瑞洛标准剂量在急性冠状动脉综合征患者中的比较：一项随机试验的结果。
Ann Intern Med. 2020 Sep 15;173(6):436-444. doi: 10.7326/M20-1806. Epub 2020 Jul 21.
4
Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.普拉格雷与替格瑞洛在经皮冠状动脉介入治疗的急性心肌梗死患者中的应用：多中心随机 PRAGUE-18 研究。
Circulation. 2016 Nov 22;134(21):1603-1612. doi: 10.1161/CIRCULATIONAHA.116.024823. Epub 2016 Aug 30.
5
Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.普拉格雷与替格瑞洛用于接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者双联抗血小板治疗的比较：一项随机对照试验的系统评价和荟萃分析
Cardiovasc Revasc Med. 2020 Dec;21(12):1613-1618. doi: 10.1016/j.carrev.2020.05.038. Epub 2020 May 28.
6
Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.普拉格雷与替格瑞洛在急性冠脉综合征患者中的头对头比较：一项随机试验的系统评价和荟萃分析
BMC Pharmacol Toxicol. 2017 Dec 12;18(1):80. doi: 10.1186/s40360-017-0189-7.
7
Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial.血小板抑制、内皮功能和 ST 段抬高型心肌梗死患者接受替格瑞洛与普拉格雷维持治疗的临床结局：REDCUE-MVI 试验的长期随访。
J Am Heart Assoc. 2020 Mar 3;9(5):e014411. doi: 10.1161/JAHA.119.014411.
8
Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.普拉格雷和替格瑞洛与氯吡格雷相比，在经皮冠状动脉介入治疗后的急性冠状动脉综合征患者中提供相同获益吗？来自随机临床试验、登记和荟萃分析的见解。
Curr Pharm Des. 2018;24(4):465-477. doi: 10.2174/1381612824666180108121834.
9
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.替格瑞洛或普拉格雷在急性冠状动脉综合征患者中的应用。
N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1.
10
The risk of dyspnea in patients treated with third-generation P2Y inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials.与氯吡格雷相比，第三代 P2Y 抑制剂治疗患者发生呼吸困难的风险：随机对照试验的荟萃分析。
BMC Cardiovasc Disord. 2020 Mar 17;20(1):140. doi: 10.1186/s12872-020-01419-y.
引用本文的文献
1
Strategies for Implementing Machine Learning Algorithms in the Clinical Practice of Radiology.在放射科的临床实践中实施机器学习算法的策略。
Radiology. 2024 Jan;310(1):e223170. doi: 10.1148/radiol.223170.
本文引用的文献
1
Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes.评估患者招募量对急性冠状动脉综合征中替格瑞洛与普拉格雷随机试验风险特征、结局和治疗效果的影响。
J Am Heart Assoc. 2021 Nov 16;10(22):e021418. doi: 10.1161/JAHA.121.021418. Epub 2021 Nov 15.
2
Reconfiguring the Cardiovascular Clinical Trial Enterprise in the United States.重新构建美国的心血管临床试验体系
JAMA Netw Open. 2021 Jul 1;4(7):e2118176. doi: 10.1001/jamanetworkopen.2021.18176.
3
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.评估大型心血管临床试验启动期间北美临床研究机构的表现。
JAMA Netw Open. 2021 Jul 1;4(7):e2117963. doi: 10.1001/jamanetworkopen.2021.17963.
4
Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials.《临床心脏病学进展 2020：重点临床试验总结》。
Adv Ther. 2021 May;38(5):2170-2200. doi: 10.1007/s12325-021-01711-z. Epub 2021 Apr 12.
5
Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry.COVID-19 大流行早期对美国医护人员的影响：来自 HERO 登记处的结果。
J Gen Intern Med. 2021 May;36(5):1319-1326. doi: 10.1007/s11606-020-06529-z. Epub 2021 Mar 10.
6
Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency.2019冠状病毒病公共卫生紧急事件期间心血管治疗的管理
J Am Coll Cardiol. 2020 Nov 24;76(21):2517-2521. doi: 10.1016/j.jacc.2020.09.594.
7
The COVID-19 pandemic: a catalyst to improve clinical trials.新冠疫情：改善临床试验的催化剂。
Nat Rev Cardiol. 2020 Nov;17(11):673-675. doi: 10.1038/s41569-020-00439-7.
8
COVID-19: An Unintended Force for Medical Revolution?新冠疫情：医学革命的一股意外力量？
J Invasive Cardiol. 2020 Apr;32(4):E81-E82. doi: 10.25270/jic/20.3204.E81. Epub 2020 Mar 25.
9
Digital clinical trials: creating a vision for the future.数字化临床试验：展望未来
NPJ Digit Med. 2019 Dec 12;2:126. doi: 10.1038/s41746-019-0203-0. eCollection 2019.
10
Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial.招募和保留对一项大型所有患者随机对照试验全因死亡率的影响：来自 GLOBAL LEADERS 试验的见解。
Clin Res Cardiol. 2020 Jul;109(7):918-929. doi: 10.1007/s00392-019-01585-w. Epub 2019 Dec 11.
Zotero 插件